From nutraceuticals to pharmaceuticals to nanopharmaceuticals: A case study in angiogenesis modulation during oxidative stress

Molecular Biotechnology

Volumn 37, Issue 1, 2007, Pages 72-80

  Mousa, Shaker A ^a   Bharali, Dhruba J ^a   Armstrong, Donald ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Angiogenesis modulation; Drug targeting; Gene delivery; Nanotechnology; Oxidative stress; Vascular disease

Indexed keywords

ANGIOGENESIS MODULATION; DRUG TARGETING; GENE DELIVERY; INFLAMMATORY PATHWAYS; NANOPHARMACEUTICALS; VASCULAR DISEASES;

DIAGNOSIS; GENES; NANOTECHNOLOGY; OXIDATIVE STRESS;

DRUG PRODUCTS;

ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COMBRESTATIN; CREMOPHOR; ENDOSTATIN; FLAVANOID; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; NANOPARTICLE; NATURAL PRODUCT; NUTRACEUTICAL; PACLITAXEL; THALIDOMIDE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER STEM CELL; CARCINOGENESIS; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; EYE DISEASE; GENE TARGETING; HUMAN; IMMUNOGENICITY; INFLAMMATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; OXIDATIVE STRESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; ANIMAL; GENE TRANSFER; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS;

EID: 35848947928     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-0064-7     Document Type: Conference Paper

References (52)

1. Parveen, S., & Sahoo, S. K. (2006). Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clinical Pharmacokinetics, 45(10), 965-988.
2. Alonso, M. J. (2004). Nanomedicines for overcoming biological barriers. Biomedicine & Pharmacotherapy, 58(3), 168-172.
3. Bishop, J. M. (1987). The molecular genetics of cancer. Science, 235(4786), 305-311.
4. Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 91, 4407-4411.
5. Miller, N., & Vile, R. (1995). Targeted vectors for gene therapy. FASEB, 9, 190-199.
6. Luo, D., & Saltzman, W. M. (2000). Synthetic DNA delivery systems. Nature Biotechnology, 18, 33-37.
7. Verma, I. M., & Somia, N. (1997). Gene therapy- promises, problems and prospects. Nature, 389, 239-242.
8. Tang, M. X., Redemann, C. T., & Szoka, F. C. Jr. (1996). In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chemistry, 7, 703-714.
9. Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proceedings of the National Academy of Sciences, 92, 7297-7301.
10. Godbey, W. T., Wu, K. K., & Mikos, A. G. (1999). Tracking the intracellular path of poly (ethylenimine)/DNA complexes for gene delivery. Proceedings of the National Academy of Sciences, 96, 5177-5181.
11. Uchegbu I. F. (2006). Pharmaceutical nanotechnology: Polymeric vesicles for drug and gene delivery. Expert Opinion on Drug Delivery, 3(5), 629-640.
12. Kneuer, C., Sameti, M., Haltner, E. G., Schiestel, T., Schirra, H., Schmidt, H., & Lehr, C. M. (2000). Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. International Journal of Pharmaceutics, 196, 257-261.
13. Jain, T. K., Roy, I., De, T. K., & Maitra, A. (1998). Nanometer silica particles encapsulating active compounds: A novel ceramic drug carrier. Journal of the American Chemical Society, 120(43), 11092-11095.
14. Graham, F. L., & Van der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenoviruses 5 DNA. Virology, 52, 456-467.
15. Orrantia, E., & Chang, P. L. (1990). Intracellular distribution of DNA internalized through calcium phosphate precipitation. Experimental Cell Research, 190, 170-174.
16. Roy, I., Mitra, S., Maitra, A., & Mozumdar, S. (2003). Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. International Journal of Pharmaceutics, 250, 25-33.
17. Sameti, M., Bohr, G., Kneuer, C., Bakowsky, U., Nacken, U., Schmidt, M., & Lehr, C. M. (2003). Stabilisation of cationically modified silica nanoparticles for gene delivery by freeze-drying. International Journal of Pharmaceutics, 266, 51-60.
18. Csogor, Z., Nacken, M., Sameti, M., Lehr, C. M., & Schmidt, H. (2003). Modified silica particles for gene delivery. Material Science and Engineering: C, 23, 93-97.
19. Luo, D., & Saltzman, W. M. (2000). Enhancement of transfection by physical concentration of DNA at the cell surface. Nature Biotechnology, 18, 893-895.
20. Bharali, D. J., Klejbor, I., Stachowiak, E. K., Dutta- Roy, P., Kaur, N., Bergey, E. J., Prasad, P. N., & Stachowiak, M. K. (2005). Organically modified silica nanoparticles: A nonviral vector for in vivo gene delivery and expression in the brain. Proceedings of the National Academy of Sciences of the United States of America, 102, 11539-11544.
21. Das, S., Jain, T. K., & Maitra, A. (2002). Inorganic-organic hybrid nanoparticles from n-octyl triethoxy silane. Journal of Colloid and Interface Science, 252, 82-88.
22. Roy, I., Ohulchanskyy, T. Y., Bharali, D. J., Pudavar, H. E., Mistretta, R. A., Kaur, N., & Prasad, P. N. (2005). Optical tracking of organically modified silica nanoparticles as DNA carriers: A nonviral, nanomedicine approach for gene delivery. Proceedings of the National Academy of Sciences of the United States of America, 102, 279-284.
23. Bruchez, M. Jr., Moronne, M., Gin, P., Weiss, S., & Alivisatos, A. P. (1998). Semiconductor nanocrystals as fluorescent biological labels. Science, 281, 2013-2016.
24. Warren, C. W., & Chan, S. N. (1998). Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science, 281, 2016-2018.
25. Akerman, M. E., Chan, W. C. W., Laakkomen, P., Bhatia, S. N., & Ruoslahti, E. (2002). Nanocrystal targeting in vivo. Proceedings of the National Academy of Sciences, 99, 12617-12621.
26. Schätzlein, A.G. (2006). Delivering cancer stem cell therapies - A role for nanomedicines? European Journal of Cancer, 42, 1309-1315.
27. Folkman, J., (1971). Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine, 285, 1182-1186.
28. Folkman, J. (1989). What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute, 82, 4-6.
29. Moehler, T. M., Ho, A. D., Goldschmidt, H., & Barlogie, B. (2003). Angiogenesis in hematologic malignancies. Critical Reviews in Oncology/Hematology, 45, 227-244.
30. Collins, T. S., & Hurwitz, H. I. (2005). Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in Oncology, 32, 61-68.
31. O'Reilly, M.S. (1997). The preclinical evaluation of angiogenesis inhibitors. Investigational New Drugs, 15, 5-13.
32. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
33. Ferrara, N., & Alitalo, K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nature Medicine, 5, 1359-1364.
34. Gale, N. W., & Yancopuolos, G. D. (1999). Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes & Development, 13, 1055-1066.
35. Streit, M., Riccardi, L., Velasco, P., Brown, L. F., Hawighorst, T., Bornstein, P., & Detmar, M. (1999). Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96, 14888-14893.
36. Kyriakides, T. R., Leach, K. J., Hoffman, A. S., Ratner, B. D., & Bornstein, P. (1999). Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proceedings of the National Academy of Sciences of the United States of America, 96, 4449-4454.
37. Panetti, T. S., Chen, H., Misenheimer, T. M., Getzler, S. B., & Mosher, D. F. (1997). Endothelial cell mitogenesis induced by LPA: Inhibition by thrombospondin-1 and thrombospondin-2. The Journal of Laboratory and Clinical Medicine, 129, 208-216.
38. Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J. J., Chen, H., Mosher, D. F., & Bouck, N. (1995). Inhibition of angiogenesis by thrombospondin-2. Biochemical and Biophysical Research Communications, 217, 326-332.
39. Armstrong, D., et al. (1998). Lipid hydroperoxide stimulates neovascularization in rabbit retina through expression of TNFa, VEGF and PDGF. Angiogenesis, 2, 93-104.
40. Ueda, T., et al. (1997). Lipid hydroperoxide and TNFa in a corneal model of neovascularization: Effect of TNFa inhibitors. Angiogenesis, 1, 174-184.
41. Carmelie, P. (2003). Angiogenesis in health and disease. Nature Medicine, 9, 653-660.
42. Yan, X., Lin, Y., Yang, D., Shen, Y., Yuan, M., Zhang, Z., Li, P., Xia, H., Li, L., Luo, D., Liu, Q., Mann, K., & Bader, B. L. (2003). A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood, 102, 184-191.
43. Hidalgo, M., & Eckhardt, S. G. (2001). Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute, 93, 178-193.
44. Prox, D., Becker, C., Pirie-Shepherd, S. R., Celik, I., Folkman, J., & Kisker, O. (2003). Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World Journal of Surgery, 27, 405-411.
45. Zhang, G. F., Wang, Y. H., Zhang, M. A., Wang, Q., Luo, Y. B., Wang, D. S., et al. (2002). Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin. Ai Zheng, 21, 50-53.
46. Katzenstein, H. M., Salwen, H. R., Nguyen, N. N., Meitar, D., & Cohn, S. L. (2001). Antiangiogenic therapy inhibits human neuroblastoma growth. Medical and Pediatric Oncology, 36, 190-193.
47. Beecken, W. D., Fernandez, A., Joussen, A. M., Achilles, E. G., Flynn, E., Lo, K. M., et al. (2001). Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. Journal of the National Cancer Institute, 93, 382-387.
48. Eder, J. P. Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., et al. (2002). Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. Journal of Clinical Oncology, 20, 3772-3784.
49. Daly, M. E., Makris, A., Reed, M., & Lewis, C. E. (2003). Hemostatic regulators of tumor angiogenesis: A source of antiangiogenic agents for cancer treatment? Journal of the National Cancer Institute, 95, 1660-1673.
50. Raje, N., & Anderson, K. (1999). Thalidomide-A revival story. The New England Journal of Medicine, 341, 1606-1609.
51. Mousa, A. S., & Mousa, S. A. (2005). Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: Role of nitric oxide and p53. Nutrition and Cancer, 53(1), 104-110.
52. Mousa, S. S., Mousa, S. S., & Mousa, S. A. (2005). Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model. Nutrition and Cancer, 52(1), 59-65.